MX2007004244A - Metodo para el aislamiento de haptoglobina. - Google Patents
Metodo para el aislamiento de haptoglobina.Info
- Publication number
- MX2007004244A MX2007004244A MX2007004244A MX2007004244A MX2007004244A MX 2007004244 A MX2007004244 A MX 2007004244A MX 2007004244 A MX2007004244 A MX 2007004244A MX 2007004244 A MX2007004244 A MX 2007004244A MX 2007004244 A MX2007004244 A MX 2007004244A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- fraction
- anion exchange
- substrate
- cohn
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 116
- 238000002955 isolation Methods 0.000 title claims abstract description 39
- 102000014702 Haptoglobin Human genes 0.000 title abstract description 20
- 108050005077 Haptoglobin Proteins 0.000 title abstract description 20
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 14
- 108010058936 Cohn fraction V Proteins 0.000 claims abstract description 11
- 230000002779 inactivation Effects 0.000 claims abstract description 8
- 239000000758 substrate Substances 0.000 claims description 67
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 40
- 238000005349 anion exchange Methods 0.000 claims description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 238000010828 elution Methods 0.000 claims description 32
- 102000001708 Protein Isoforms Human genes 0.000 claims description 27
- 108010029485 Protein Isoforms Proteins 0.000 claims description 27
- 238000005406 washing Methods 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 21
- 235000017281 sodium acetate Nutrition 0.000 claims description 20
- 102000009027 Albumins Human genes 0.000 claims description 19
- 108010088751 Albumins Proteins 0.000 claims description 19
- 239000000356 contaminant Substances 0.000 claims description 19
- 239000000872 buffer Substances 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 238000011068 loading method Methods 0.000 claims description 16
- 239000012149 elution buffer Substances 0.000 claims description 15
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 14
- 239000001632 sodium acetate Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 239000011534 wash buffer Substances 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- 239000003599 detergent Substances 0.000 claims description 12
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000011100 viral filtration Methods 0.000 claims description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 2
- 239000006174 pH buffer Substances 0.000 claims 4
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 claims 3
- 102000050796 human HP Human genes 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 13
- 229960000583 acetic acid Drugs 0.000 description 12
- 239000003446 ligand Substances 0.000 description 11
- 229920002271 DEAE-Sepharose Polymers 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 7
- 235000011130 ammonium sulphate Nutrition 0.000 description 7
- 150000003278 haem Chemical class 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000006096 absorbing agent Substances 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 238000011141 high resolution liquid chromatography Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 239000012619 Butyl Sepharose® Substances 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002594 sorbent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022822 Intravascular haemolysis Diseases 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000002479 acid--base titration Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229920006321 anionic cellulose Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920005565 cyclic polymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 102000036073 hemoglobin binding proteins Human genes 0.000 description 1
- 108091010989 hemoglobin binding proteins Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Semiconductor Lasers (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0423196.5A GB0423196D0 (en) | 2004-10-19 | 2004-10-19 | Method |
| PCT/GB2005/004037 WO2006043062A1 (en) | 2004-10-19 | 2005-10-19 | Method for the isolation of haptoglobin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007004244A true MX2007004244A (es) | 2007-09-07 |
Family
ID=33484812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007004244A MX2007004244A (es) | 2004-10-19 | 2005-10-19 | Metodo para el aislamiento de haptoglobina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9145448B2 (enExample) |
| EP (1) | EP1802654B1 (enExample) |
| JP (1) | JP4950053B2 (enExample) |
| AT (1) | ATE539085T1 (enExample) |
| AU (1) | AU2005297061B2 (enExample) |
| BR (1) | BRPI0516933B8 (enExample) |
| CA (1) | CA2584407C (enExample) |
| ES (1) | ES2379157T3 (enExample) |
| GB (1) | GB0423196D0 (enExample) |
| IL (1) | IL182340A (enExample) |
| MX (1) | MX2007004244A (enExample) |
| PL (1) | PL1802654T3 (enExample) |
| WO (1) | WO2006043062A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0423196D0 (en) | 2004-10-19 | 2004-11-24 | Nat Blood Authority | Method |
| US9534029B2 (en) | 2012-10-03 | 2017-01-03 | Csl Behring Ag | Method of purifying proteins |
| HK1212995A1 (zh) * | 2012-10-03 | 2016-06-24 | Csl Behring Ag | 一种纯化蛋白质的方法 |
| EP3917943A4 (en) * | 2019-02-01 | 2022-12-07 | Ohio State Innovation Foundation | PROTEINS PURIFICATION PROCEDURES |
| US20220218834A1 (en) * | 2019-05-20 | 2022-07-14 | Ohio State Innovation Foundation | Apohemoglobin-haptoglobin complexes and methods of using thereof |
| US20240034749A1 (en) * | 2021-02-04 | 2024-02-01 | Green Cross Corporation | Method for purification of hemopexin and haptoglobin |
| CN115531921B (zh) * | 2022-08-26 | 2024-07-16 | 大连依利特分析仪器有限公司 | 一种制备型液相色谱馏分收集装置及方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4061735A (en) * | 1973-11-15 | 1977-12-06 | The Green Cross Corporation | Haptoglobin in aqueous solution and process for preparing the same |
| GB1426039A (en) | 1973-11-15 | 1976-02-25 | Green Cross Corp | Haptoglobin in aqueous solution and process for tits preparation |
| US4137307A (en) * | 1973-11-15 | 1979-01-30 | The Green Cross Corporation | Process for preparing haptoglobin aqueous solution using strong anion exchanger |
| JPS5337406B2 (enExample) * | 1973-11-15 | 1978-10-09 | ||
| JPS52128205A (en) * | 1976-04-16 | 1977-10-27 | Green Cross Corp:The | Prophylactic and therapeutic drugs for cerebro-vascular contraction |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| US5094960A (en) * | 1988-10-07 | 1992-03-10 | New York Blood Center, Inc. | Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography |
| JP3554796B2 (ja) * | 1988-10-31 | 2004-08-18 | 三菱ウェルファーマ株式会社 | アルブミン製剤及びその製造方法 |
| JP3825061B2 (ja) * | 1994-09-28 | 2006-09-20 | 三菱ウェルファーマ株式会社 | ハプトグロビンの製造方法 |
| DE19960500A1 (de) * | 1999-12-15 | 2001-07-12 | Giesing Michael | Antikörper und Verfahren zu ihrer Herstellung, deren Verwendung sowie Immunisierungscocktails, Immunoassay-Sets und Peptide |
| PT1328297E (pt) * | 2000-10-16 | 2010-01-04 | Cytoguide Aps | Função de um receptor de haptoglobina-hemoglobina e suas utilizações |
| US20030113830A1 (en) | 2001-07-11 | 2003-06-19 | Rappaport Family Institute For Research In The Medical Sciences | Novel antioxidant, nucleic acid constructs encoding same, pharmaceutical compositions containing same and use of same for reducing oxidative-stress |
| JP2004244348A (ja) * | 2003-02-13 | 2004-09-02 | Nihon Pharmaceutical Co Ltd | パプトグロビンの精製法 |
| GB0423196D0 (en) | 2004-10-19 | 2004-11-24 | Nat Blood Authority | Method |
| WO2006107708A1 (en) | 2005-04-04 | 2006-10-12 | Alexion Pharmaceuticals, Inc. | Treatment of disease caused by excess free hemoglobin |
-
2004
- 2004-10-19 GB GBGB0423196.5A patent/GB0423196D0/en not_active Ceased
-
2005
- 2005-10-19 US US11/577,478 patent/US9145448B2/en active Active
- 2005-10-19 CA CA2584407A patent/CA2584407C/en not_active Expired - Lifetime
- 2005-10-19 ES ES05794729T patent/ES2379157T3/es not_active Expired - Lifetime
- 2005-10-19 BR BRPI0516933A patent/BRPI0516933B8/pt active IP Right Grant
- 2005-10-19 AU AU2005297061A patent/AU2005297061B2/en not_active Ceased
- 2005-10-19 MX MX2007004244A patent/MX2007004244A/es active IP Right Grant
- 2005-10-19 WO PCT/GB2005/004037 patent/WO2006043062A1/en not_active Ceased
- 2005-10-19 EP EP05794729A patent/EP1802654B1/en not_active Expired - Lifetime
- 2005-10-19 JP JP2007537377A patent/JP4950053B2/ja not_active Expired - Lifetime
- 2005-10-19 AT AT05794729T patent/ATE539085T1/de active
- 2005-10-19 PL PL05794729T patent/PL1802654T3/pl unknown
-
2007
- 2007-03-29 IL IL182340A patent/IL182340A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0516933B8 (pt) | 2021-05-25 |
| JP4950053B2 (ja) | 2012-06-13 |
| BRPI0516933A (pt) | 2008-09-23 |
| ES2379157T3 (es) | 2012-04-23 |
| IL182340A0 (en) | 2007-07-24 |
| EP1802654B1 (en) | 2011-12-28 |
| AU2005297061A1 (en) | 2006-04-27 |
| EP1802654A1 (en) | 2007-07-04 |
| JP2008517046A (ja) | 2008-05-22 |
| CA2584407C (en) | 2015-02-03 |
| AU2005297061B2 (en) | 2011-09-01 |
| US20090281282A1 (en) | 2009-11-12 |
| IL182340A (en) | 2012-06-28 |
| BRPI0516933B1 (pt) | 2021-02-09 |
| CA2584407A1 (en) | 2006-04-27 |
| GB0423196D0 (en) | 2004-11-24 |
| WO2006043062A1 (en) | 2006-04-27 |
| ATE539085T1 (de) | 2012-01-15 |
| US9145448B2 (en) | 2015-09-29 |
| PL1802654T3 (pl) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4445202B2 (ja) | 治療的使用のためのヒト免疫グロブリン濃縮物の調製方法 | |
| USRE43655E1 (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
| KR100501263B1 (ko) | 정맥 주사용 면역글로불린의 제조 방법 및 그 외의 면역글로불린 제품 | |
| JP6876655B2 (ja) | タンパク質の精製方法 | |
| JP2002517516A (ja) | 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法 | |
| US20030152966A1 (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
| CN103153333B (zh) | 补体因子h的纯化方法 | |
| FR2676231A1 (fr) | Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation. | |
| PL165402B1 (pl) | Sposób wydzielania oczyszczonego roztworu albuminy PL | |
| AU2005297061B2 (en) | Method for the isolation of haptoglobin | |
| EP1419177B1 (en) | A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine | |
| AU2006321447B2 (en) | Method for the purification of alpha-1-antitrypsin | |
| HK40050028A (en) | A method of purifying proteins | |
| NZ731196B2 (en) | A novel purification process for isolation and commercial production of recombinant tnk-tpa (tenecteplase) | |
| WO2000043412A1 (en) | Compositions containing highly purified heparin cofactor ii and method for separating the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |